Structural mechanism of a drug-binding process involving a large conformational change of the protein target

Nat Commun. 2023 Apr 5;14(1):1885. doi: 10.1038/s41467-023-36956-5.

Abstract

Proteins often undergo large conformational changes when binding small molecules, but atomic-level descriptions of such events have been elusive. Here, we report unguided molecular dynamics simulations of Abl kinase binding to the cancer drug imatinib. In the simulations, imatinib first selectively engages Abl kinase in its autoinhibitory conformation. Consistent with inferences drawn from previous experimental studies, imatinib then induces a large conformational change of the protein to reach a bound complex that closely resembles published crystal structures. Moreover, the simulations reveal a surprising local structural instability in the C-terminal lobe of Abl kinase during binding. The unstable region includes a number of residues that, when mutated, confer imatinib resistance by an unknown mechanism. Based on the simulations, NMR spectra, hydrogen-deuterium exchange measurements, and thermostability measurements and estimates, we suggest that these mutations confer imatinib resistance by exacerbating structural instability in the C-terminal lobe, rendering the imatinib-bound state energetically unfavorable.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Benzamides
  • Drug Resistance, Neoplasm / genetics
  • Fusion Proteins, bcr-abl
  • Imatinib Mesylate
  • Molecular Dynamics Simulation
  • Piperazines* / pharmacology
  • Protein Kinase Inhibitors / pharmacology
  • Pyrimidines / pharmacology

Substances

  • Imatinib Mesylate
  • Piperazines
  • Pyrimidines
  • Benzamides
  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Fusion Proteins, bcr-abl